Global Collaboration: This article is written as a Moroccan Medical Cannabis Company to use as a reference guide only.
At a glance
- We co-develop with universities, biotech innovators, and pharmaceutical distributors across multiple regions.
- Collaboration spans research, product development, clinical evidence, regulatory alignment, and market access.
- Every partnership is grounded in quality (GACP/GMP/ISO), data transparency, and patient impact.
Why Morocco—and why we work globally
Morocco’s climate, agronomic heritage, and modern regulatory evolution make it an ideal base for pharmaceutical-grade cannabis. But medicines are global by nature. To deliver consistent, evidence-based therapies, we partner internationally—sharing know-how, validating science, and meeting the highest regulatory expectations wherever patients live.
Our collaboration model
- Academic research partnerships
- We co-design preclinical and clinical studies with universities in Morocco and abroad. Joint workstreams typically include:
- Pharmacology & mechanism studies: cannabinoid/terpene interactions, target engagement, and dose–response modelling.
- Analytical science: method development for potency, impurities, and stability under ISO/IEC 17025 frameworks.
- Clinical outcomes: pragmatic trials and real-world registries in pain, spasticity, and paediatric epilepsies (with strict governance).
- Biotech co-development
- With biotech firms, we explore:
- Novel formulations: improved bioavailability oils, oromucosal sprays, and precision-release capsules.
- Process intensification: greener extraction, solvent recovery, and terpene preservation.
- Companion diagnostics & digital therapeutics: symptom tracking, adherence tools, and AI-assisted titration.
- Pharmaceutical distribution alliances
- We work with GDP-compliant distributors to secure:
- Qualified lanes with temperature mapping and data-logged shipments.
- QP release for EU markets and equivalent oversight elsewhere.
- Pharmacovigilance integration to detect and share safety signals promptly.
Global Collaboration
What each partner brings—and gains
- Universities: scientific rigour, independent ethics review, and talent pipelines. In return, they gain access to standardised study drugs, funding for labs, and opportunities for co-authorship.
- Biotech companies: platform technologies (delivery systems, analytics, software). They benefit from scale, GMP manufacturing, and real-world patient datasets.
- Distributors & hospital pharmacies: regulatory reach and last-mile logistics; they receive transparent batch documentation, stability updates, and medical information support.
Quality and compliance as a shared language
Partnerships only work if the quality systems align. We operate to GACP standards in cultivation and to GMP standards in manufacturing, supported by ISO/IEC 17025 laboratory methods. Each collaboration begins with:
- Technical Quality Agreements defining roles for testing, release, deviations, and recall.
- Data integrity rules (ALCOA+) and validated digital systems (ERP/MES/LIMS).
- Joint audits & training to harmonise SOPs across sites.
Clinical evidence and data transparency
We prioritise evidence that clinicians can use:
- Prospective registries built with academic partners, capturing outcomes, quality-of-life metrics, and safety events.
- Protocol sharing: de-identified analysis plans and pre-registered endpoints.
- Open partner dashboards: batch CoAs, stability status, and change-control logs accessible to approved stakeholders.
Traceability and technology transfer
Every plant, lot, and finished pack has a digital footprint:
- GS1 serialisation and seed-to-sale identifiers link raw material to patient pack.
- Secure partner APIs expose real-time release data, excursion reports, and inventory.
- Technology transfer playbooks (IQ/OQ/PQ, cleaning validation, method validation) ensure that when we scale with a partner, quality scales too.
Sustainability and ethical sourcing—done together.
We co-set environmental KPIs with partners:
- Energy & water intensity per kilogram of finished product.
- Waste reduction through solvent recycling and media reclamation.
- Local employment and skills uplift, including GMP upskilling programmes and scholarships for science graduates.
Global Collaboration
Illustrative collaboration pathways
- Discovery to clinic: University lab identifies a promising cannabinoid profile → joint formulation with a biotech partner → Phase II investigator-initiated trial under our GMP supply and PV oversight.
- Market entry in a new region: We pair with a GDP distributor → adapt labelling to local rules → integrate pharmacovigilance → roll out clinician education and patient support materials.
- Manufacturing scale-up: Shared tech transfer to a partner’s site → method bridging and comparability studies → dual-site supply for resilience.
Governance that protects patients and partners
- Ethics & oversight: Independent ethics committees and medical advisory boards review study designs and safety data.
- IP & confidentiality: Balanced agreements safeguard partner IP while encouraging publication of non-confidential scientific findings.
- Risk management: Joint risk registers covering supply, regulatory, cybersecurity, and business continuity—with rehearsed recall drills.
How we choose partners
We look for:
- Demonstrated quality culture (not just certificates).
- Openness to data sharing and measurement-based care.
- Complementary strengths—be it a niche formulation, regional distribution depth, or academic expertise.
- A shared commitment to patient access and equitable pricing.
Benefits for patients, clinicians, and health systems
- Patients: safer, more consistent medicines and clearer information.
- Clinicians: evidence they can trust and straightforward medical information channels.
- Health systems: compliance confidence, reliable supply, and transparent cost–value narratives.
Let’s build the following study, product, or pathway—together.
Whether you’re a university PI planning a trial, a biotech with a delivery platform, or a distributor ready to open a new market, we’re set up to collaborate—from due diligence to day-one supply. Share your objectives, and we’ll map a joint plan with timelines, responsibilities, and measurable outcomes.
Contact our partnerships team.
- Academic collaborations: protocol development, materials transfer, and grant co-applications.
- Biotech co-development: formulation dossiers, tech transfer, and GMP slotting.
- Distribution & access: QP release pathways, tender support, and PV integration.
Together, we can translate Morocco’s strengths—and global expertise—into high-quality, evidence-led cannabis medicines for patients everywhere.
Global Collaboration